AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

PISETSKY MICHAEL A. sold $52K of SIBN

PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 3,134 shares of SI-BONE, Inc. (SIBN) at an average of $16.71 ($16.70–$16.86) across 3 trades on 2026-07-02.

Original reporting
SEC EDGAR · PISETSKY MICHAEL A.
Published Jul 6, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

This adds incremental information about insider activity (open-market sale by an SVP/Chief Legal Officer) but does not introduce new operational or financial guidance.

02

Market read

Traders may monitor insider activity for sentiment, but the filing alone is unlikely to drive a durable repricing without accompanying company-specific catalysts.

03

What to watch

Transaction size ($52.4K) is relatively small versus typical institutional flows, and the article provides no follow-on insider buys or concurrent operational news.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-02.

Background

The article is a SEC Form 4 insider transaction disclosure for SI-BONE, Inc. (SIBN).

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SI-BONE insider Michael A. Pisetsky sold $52.4K of SIBN shares in an open-market transaction on 2026-07-02.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than earnings- or guidance-driven.

Evidence & confidence

The filing discloses transaction size ($52.4K) and role, but provides no new company performance, guidance, or legal/operational development.

Market effects

Sector

None—this is company-specific insider transaction data, not a sector-wide signal.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale could be for diversification, taxes, or planned liquidity needs; without a 10b5-1 plan, it still may not indicate negative fundamentals.

Key entities

  • issuer
    SI-BONE, Inc.

    Company whose insider transaction is disclosed via Form 4.

  • insider
    Michael A. Pisetsky

    SVP, Ops & Adm / Chief Legal Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com